Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$7.41 USD

7.41
510,583

+0.42 (6.01%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $7.24 -0.17 (-2.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks News

Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View

Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.

Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3

Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.

Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip

Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.

Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates

Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.

Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss

Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.

Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster

Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.

QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark

QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.

Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates

Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.

Omnicell Solid on Geographic Expansion Amid Stiff Competition

Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.

AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View

IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.

PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y

PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.

McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View

McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.

Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet

Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.

Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top

Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.

Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top

Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.

ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum

ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised

Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.

Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid

Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.

AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View

AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.

Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4

Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.

Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4

Thermo Fisher (TMO) gains on growth in all business segments in Q4.

Align Technology (ALGN) Beats on Earnings and Revenues in Q4

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q4.

Varian Strong on Global Expansion and Proton Therapy Arm

Varian's (VAR) strong presence in China instills optimism in the stock.

Stryker (SYK) Q4 Earnings Beat, International Revenues Surge

Stryker (SYK) gains from solid segmental contributions in Q4.